It was demonstrated that metformin exerts anticancer effects on ovarian cancer cells by inhibiting MSLN-mediated interlukin6 (IL6)/ Signal Transducer and Activator Protein (STAT3) signaling, along with downregulation of vascular endothelial growth factor (VEGF) and transforming Growth Factor beta1 (TGFb1) [19]. Here, VEGFA is linked to ovarian carcinoma.